The UK Medicines and Healthcare products Regulatory Agency (MHRA), Australian Therapeutic Goods Administration (TGA) and Health Canada approve KIMMTRAK® (tebentafusp) for the treatment of unresectable or metastatic uveal melanoma
June 08, 2022 07:00 ET
|
Immunocore Holdings Limited
The UK Medicines and Healthcare products Regulatory Agency (MHRA), Australian Therapeutic Goods Administration (TGA) and Health Canada approve KIMMTRAK® (tebentafusp) for the treatment of unresectable...
Immunocore announces clinical trial collaboration with Sanofi to evaluate Sanofi’s product candidate SAR444245, non-alpha IL-2, in combination with KIMMTRAK® in patients with metastatic cutaneous melanoma
June 03, 2022 07:00 ET
|
Immunocore Holdings Limited
Immunocore announces clinical trial collaboration with Sanofi to evaluate Sanofi’s product candidate SAR444245, non-alpha IL-2, in combination with KIMMTRAK® in patients with metastatic cutaneous...
New Study Demonstrates Integrin Activation Can Bring the Heat to Cold Melanoma Tumors
May 18, 2022 19:23 ET
|
7 Hills Pharma
HOUSTON, May 18, 2022 (GLOBE NEWSWIRE) -- 7 Hills Pharma LLC (“7 Hills” or “7HP”), together with The University of Texas MD Anderson Cancer Center (“MD Anderson”) and Texas Heart Institute (“THI”),...
Idera Pharmaceuticals Shares Positive Results from Investigator-Sponsored Trial in Melanoma Patients at Amsterdam UMC
May 17, 2022 08:04 ET
|
Idera Pharmaceuticals, Inc.
EXTON, Pa., May 17, 2022 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera,” “we,” and “our”) (Nasdaq: IDRA) today shared positive interim results from Amsterdam UMC, Vrije Universiteit...
MacroGenics Provides Update on Corporate Progress and First Quarter 2022 Financial Results
May 03, 2022 16:01 ET
|
MacroGenics, Inc.
Plan to start Phase 2/3 prostate cancer study with MGC018 by year-end Initiated Phase 1 study of MGC018 in combination with lorigerlimab in advanced solid tumorsTargeting mid-2022 start of Phase 1...
Global Immune Checkpoint Inhibitors Market to 2027 - Size, Share & Industry Trends Analysis Report
April 26, 2022 06:43 ET
|
Research and Markets
Dublin, April 26, 2022 (GLOBE NEWSWIRE) -- The "Global Immune Checkpoint Inhibitors Market Size, Share & Industry Trends Analysis Report By Application (Lung Cancer, Bladder Cancer, Melanoma,...
Peptide Cancer Vaccine Market to Reach USD 10.07 Billion by 2028 - Vast Usage of Peptide Vaccine to Control Tumour Growth Propels the Market Demand – Vantage Market Research
February 15, 2022 03:33 ET
|
Vantage Market Research
WASHINGTON, Feb. 15, 2022 (GLOBE NEWSWIRE) -- Vantage Market Research’s recent analysis of the Global Peptide Cancer Vaccine Market finds that Peptide Cancer Vaccine aids to provide tumour-specific...
Oncotelic Initiates Phase 1 Trial Evaluating CA4P in Combination with Pembrolizumab for Melanoma
January 05, 2022 08:01 ET
|
Oncotelic Therapeutics, Inc.
AGOURA HILLS, Calif., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. ("Oncotelic" or the "Company") (OTCQB:OTLC), a leading developer of TGF-β therapeutics for oncology and virology,...
Worldwide Immuno Oncology Assays Industry to 2026 - Clinical Trials to Cure Different Cancers in Immunotherapy Presents Opportunities
January 05, 2022 06:38 ET
|
Research and Markets
Dublin, Jan. 05, 2022 (GLOBE NEWSWIRE) -- The "Immuno Oncology Assays Market Research Report by Indication, Product, Technology, Application, and Region - Global Forecast to 2026 - Cumulative Impact...
Tyrokinse Kinase Inhibitors in the Global Oncology Market 2021: Market Leaders by Indication and Product
November 05, 2021 05:58 ET
|
Research and Markets
Dublin, Nov. 05, 2021 (GLOBE NEWSWIRE) -- The "Oncology Markets for Tyrokinse Kinase Inhibitors" report has been added to ResearchAndMarkets.com's offering. Traditional cancer therapy has focused...